C. Eric Winzer - 04 Mar 2022 Form 4 Insider Report for Nuo Therapeutics, Inc. (AURX)

Reporting relationship
Director
Issuer ticker
AURX
Reported as of
04 Mar 2022
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
26 Apr 2022, 21:34:28 UTC
Next SEC filing
22 Jul 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ David E. Jorden, attorney-in-fact
Filing notes and source

Key filing fact

C. Eric Winzer filed Form 4 for Nuo Therapeutics, Inc. (AURX) on 26 Apr 2022.

Key facts

  • This page summarizes C. Eric Winzer's Form 4 filing for Nuo Therapeutics, Inc. (AURX).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 26 Apr 2022, 21:34.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AURX transaction Derivative

Option to Purchase Common Stock

Award

Transaction value
$0
Shares
+36,666
Change %
Price
$0.000000
Shares after
36,666
Date
04 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
36,666
Exercise price
$0.5000
Footnotes
F1
AURX transaction Derivative

Option to Purchase Common Stock

Award

Transaction value
$0
Shares
+75,000
Change %
Price
$0.000000
Shares after
75,000
Date
04 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
75,000
Exercise price
$0.7500
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Granted in settlement of compensation liability for period January 1, 2019 through April 30, 2019

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .